Home/Filings/4/A/0001209191-18-006131
4/A//SEC Filing

Celgene Alpine Investment Co., LLC 4/A

Accession 0001209191-18-006131

CIK 0001439222other

Filed

Jan 30, 7:00 PM ET

Accepted

Jan 31, 8:39 AM ET

Size

11.0 KB

Accession

0001209191-18-006131

Insider Transaction Report

Form 4/AAmended
Period: 2018-01-23
Transactions
  • Purchase

    Common Stock

    2018-01-23$67.00/sh+851,154$57,027,3181,374,599 total
Holdings
  • Common Stock

    (indirect: See footnote)
    5,343,834
Transactions
  • Purchase

    Common Stock

    2018-01-23$67.00/sh+851,154$57,027,3181,374,599 total
Holdings
  • Common Stock

    (indirect: See footnote)
    5,343,834
Transactions
  • Purchase

    Common Stock

    2018-01-23$67.00/sh+851,154$57,027,3181,374,599 total
Holdings
  • Common Stock

    (indirect: See footnote)
    5,343,834
Transactions
  • Purchase

    Common Stock

    2018-01-23$67.00/sh+851,154$57,027,3181,374,599 total
Holdings
  • Common Stock

    (indirect: See footnote)
    5,343,834
Footnotes (2)
  • [F1]This Form 4 Amendment is being submitted to correct the date of earliest transaction in box 3 to reflect January 23, 2018.
  • [F2]Of these shares, 624,575 shares are owned directly by Celgene Switzerland LLC, 708,333 shares are owned directly by Celgene Alpine Investment Co. LLC, and 4,010,926 shares are owned directly by Celgene European Investment Company LLC, each a wholly-owned subsidiary of Celgene Corporation ("Celgene"), and Celgene has the power to vote, acquire, hold and dispose of all such shares. Celgene disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

Issuer

AGIOS PHARMACEUTICALS INC

CIK 0001439222

Entity typeother
IncorporatedDE

Related Parties

1
  • filerCIK 0001581774

Filing Metadata

Form type
4/A
Filed
Jan 30, 7:00 PM ET
Accepted
Jan 31, 8:39 AM ET
Size
11.0 KB